Study of U101 for Bladder Pain and/or Urgency

Inclusion Criteria: * Male and female subjects at least 18 years of age. * Subjects must have given written informed consent to participate in this trial. * All female subjects, except those who are post-menopausal and/or surgically sterilized, must consent to use two medically acceptable methods of contraception throughout the entire study period. Medically acceptable methods of contraception that may be used by the subject and/or her partner include: abstinence, birth control pills, diaphragm with spermicide, intrauterine device (IUD), condom and foam, vaginal spermicidal suppository, progestin implant, and Depo-Provera injections. * Subjects must have had symptoms of pelvic pain and/or urgency. * Medical history and physical examination results must be clinically acceptable to the Investigator. Medical Monitor may evaluate subjects who don't meet eligibility criteria. * Female subjects currently using hormone therapy (HT) must have been using HT for at least 3 months. Exclusion Criteria: * Subjects less than 18 years of age. * Subjects with known hypersensitivity to heparin or lidocaine. * Female subjects who have a positive pregnancy test at the time of screening, who are pregnant or lactating, or who are planning to become pregnant during the study period. * Subjects who are chronic users of narcotics or who are using any narcotics at the time of study entry. * Subjects who have hepatic disease or clinically significant abnormal liver function tests (more than twice the upper limit of the normal range). * Subjects who do not expect to be available for the entire duration of the study. * Subjects with any coexisting significant medical condition that is likely to interfere with study procedures (cardiovascular, hematological, central nervous system, pulmonary, renal, etc.) * Subjects who have been treated with dimethyl sulfoxide (DMSO) or other bladder instillation therapies within three months prior to study entry. * Subjects who have had cystoscopic dilatation of their bladder or urethra within three months of study entry. * Subjects who have taken or used any investigational drug or device within 30 days before the start of the study, or who are currently enrolled in another investigational study. * Subjects contemplating having or scheduled for any invasive surgical procedures during the study period. * Subjects who are unwilling or unable to abide by the requirements of the study. * History of gastrointestinal (GI) bleeding * Active bleeding from any source * Screening activated partial thromboplastin time (aPTT) above normal limits * Systolic blood pressure (BP) \> 180 mmHg or \< 90 mmHg at Screening. * Subjects with an actively bleeding lesion/area in the bladder as detected by urinalysis